Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:

• AIM ImmunoTech (AIM), 1,863% surge in interest

Pipeline and key clinical candidates for these companies:

AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The company’s lead product is a first-in-class investigational drug called Ampligen, a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

Recent news on these stocks:

July 29

AIM ImmunoTech announced the pricing of a public offering of an aggregate of 2,000,000 shares of its common stock, Class E warrants to purchase up to 2,000,000 shares of common stock, and Class F warrants to purchase up to 2,000,000 shares of common stock, at a combined public offering price of $4.00 per share and accompanying warrants. The warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance. The Class E warrants will expire on the fifth anniversary of the original issuance date, and the Class F warrants will expire on the eighteen-month anniversary of the original issuance date. The closing of the offering is expected to occur on or about July 30, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds, before deducting placement agent fees and offering expenses, are expected to be approximately $8M. Maxim Group is acting as sole placement agent in connection with this offering.

July 28

AIM ImmunoTech reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX. The DURIPANC study – which is a joint collaboration with AstraZeneca and Erasmus Medical Center in the Netherlands – is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion. Compared to these data, the DURIPANC study mid-year report shows continuing promising early signs of both no significant toxicity and superior PFS and OS: No significant toxicity, an encouraging safety profile for a post-chemo setting; ~21% of patients have PFS greater than6 months, with an additional 21% not yet progressed; and OS greater than6 months in the majority of eligible patients-better than expected in this setting.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.